Kidney Outcomes in Patients With Hereditary Transthyretin Amyloid Nephropathy Treated With Transthyretin Stabilizers And Gene-Silencer Therapies
Julien Dang(Inserm), Vincent Audard(Inserm), Noémie Jourde‐Chiche(Aix-Marseille Université), Anissa Moktefi(Inserm), Charlotte Mussini(Assistance Publique – Hôpitaux de Paris), Albane Brodin-Sartorius(Assistance Publique – Hôpitaux de Paris), Ilias Kounis(Assistance Publique – Hôpitaux de Paris), Mohamad Zaidan(Délégation Paris 5), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Perrine Devic(Hospices Civils de Lyon), Mickaël Bobot(Inserm), Andoni Echaniz-Laguna(Assistance Publique – Hôpitaux de Paris), Sarah Mouawad(Université Paris-Saclay), Justine Solignac(Inserm), Sophie Ferlicot(Université Paris-Sud), Thibaud Damy(Amyloidosis Foundation), Renaud Snanoudj(Assistance Publique – Hôpitaux de Paris), Céline Labeyrie(Bicêtre Hospital), Frank Bridoux(Université de Poitiers), Laurent Daniel(Hôpital de la Conception), Marie Essig, Antoine Huart, Cécile Cauquil(Assistance Publique – Hôpitaux de Paris), Delphine Campigli(Inserm), Hamza Sakhi(Hôpital Necker-Enfants Malades)
Cited by 4
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k